Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 62

1.

Identification and evaluation of antivirals for Rift Valley fever virus.

Lang Y, Li Y, Jasperson D, Henningson J, Lee J, Ma J, Li Y, Duff M, Liu H, Bai D, McVey S, Richt JA, Ikegami T, Wilson WC, Ma W.

Vet Microbiol. 2019 Mar;230:110-116. doi: 10.1016/j.vetmic.2019.01.027. Epub 2019 Jan 29.

PMID:
30827375
2.

Experimental Infection of Syrian Hamsters With Aerosolized Nipah Virus.

Escaffre O, Hill T, Ikegami T, Juelich TL, Smith JK, Zhang L, Perez DE, Atkins C, Park A, Lawrence WS, Sivasubramani SK, Peel JE, Peterson JW, Lee B, Freiberg AN.

J Infect Dis. 2018 Oct 5;218(10):1602-1610. doi: 10.1093/infdis/jiy357.

PMID:
29912426
3.

Favipiravir (T-705) protects against Nipah virus infection in the hamster model.

Dawes BE, Kalveram B, Ikegami T, Juelich T, Smith JK, Zhang L, Park A, Lee B, Komeno T, Furuta Y, Freiberg AN.

Sci Rep. 2018 May 15;8(1):7604. doi: 10.1038/s41598-018-25780-3.

4.

Rift Valley fever vaccines: current and future needs.

Dungu B, Lubisi BA, Ikegami T.

Curr Opin Virol. 2018 Apr;29:8-15. doi: 10.1016/j.coviro.2018.02.001. Epub 2018 Mar 4. Review.

PMID:
29514112
5.

Distinct virulence of Rift Valley fever phlebovirus strains from different genetic lineages in a mouse model.

Ikegami T, Balogh A, Nishiyama S, Lokugamage N, Saito TB, Morrill JC, Shivanna V, Indran SV, Zhang L, Smith JK, Perez D, Juelich TL, Morozov I, Wilson WC, Freiberg AN, Richt JA.

PLoS One. 2017 Dec 21;12(12):e0189250. doi: 10.1371/journal.pone.0189250. eCollection 2017.

6.

Genetic stability of Rift Valley fever virus MP-12 vaccine during serial passages in culture cells.

Lokugamage N, Ikegami T.

NPJ Vaccines. 2017;2. pii: 20. doi: 10.1038/s41541-017-0021-9. Epub 2017 Jul 17.

7.

Attenuation and protective efficacy of Rift Valley fever phlebovirus rMP12-GM50 strain.

Ly HJ, Nishiyama S, Lokugamage N, Smith JK, Zhang L, Perez D, Juelich TL, Freiberg AN, Ikegami T.

Vaccine. 2017 Dec 4;35(48 Pt B):6634-6642. doi: 10.1016/j.vaccine.2017.10.036. Epub 2017 Oct 20.

8.

Risk analysis of inter-species reassortment through a Rift Valley fever phlebovirus MP-12 vaccine strain.

Ly HJ, Lokugamage N, Nishiyama S, Ikegami T.

PLoS One. 2017 Sep 19;12(9):e0185194. doi: 10.1371/journal.pone.0185194. eCollection 2017.

9.

Contribution of Human Lung Parenchyma and Leukocyte Influx to Oxidative Stress and Immune System-Mediated Pathology following Nipah Virus Infection.

Escaffre O, Saito TB, Juelich TL, Ikegami T, Smith JK, Perez DD, Atkins C, Levine CB, Huante MB, Nusbaum RJ, Endsley JJ, Freiberg AN, Rockx B.

J Virol. 2017 Jul 12;91(15). pii: e00275-17. doi: 10.1128/JVI.00275-17. Print 2017 Aug 1.

10.

Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate.

Ikegami T.

Expert Rev Vaccines. 2017 Jun;16(6):601-611. doi: 10.1080/14760584.2017.1321482. Epub 2017 May 2. Review.

11.

Rift Valley fever virus NSs protein functions and the similarity to other bunyavirus NSs proteins.

Ly HJ, Ikegami T.

Virol J. 2016 Jul 2;13:118. doi: 10.1186/s12985-016-0573-8. Review.

12.

Attenuation of pathogenic Rift Valley fever virus strain through the chimeric S-segment encoding sandfly fever phlebovirus NSs or a dominant-negative PKR.

Nishiyama S, Slack OA, Lokugamage N, Hill TE, Juelich TL, Zhang L, Smith JK, Perez D, Gong B, Freiberg AN, Ikegami T.

Virulence. 2016 Nov 16;7(8):871-881. Epub 2016 Jun 1.

13.

Mutational Analysis of the Rift Valley Fever Virus Glycoprotein Precursor Proteins for Gn Protein Expression.

Phoenix I, Lokugamage N, Nishiyama S, Ikegami T.

Viruses. 2016 May 24;8(6). pii: E151. doi: 10.3390/v8060151.

14.

N-Glycans on the Rift Valley Fever Virus Envelope Glycoproteins Gn and Gc Redundantly Support Viral Infection via DC-SIGN.

Phoenix I, Nishiyama S, Lokugamage N, Hill TE, Huante MB, Slack OA, Carpio VH, Freiberg AN, Ikegami T.

Viruses. 2016 May 23;8(5). pii: E149. doi: 10.3390/v8050149.

15.

Application of Droplet Digital PCR to Validate Rift Valley Fever Vaccines.

Ly HJ, Lokugamage N, Ikegami T.

Methods Mol Biol. 2016;1403:207-20. doi: 10.1007/978-1-4939-3387-7_10.

PMID:
27076132
16.

The L, M, and S Segments of Rift Valley Fever Virus MP-12 Vaccine Independently Contribute to a Temperature-Sensitive Phenotype.

Nishiyama S, Lokugamage N, Ikegami T.

J Virol. 2016 Jan 27;90(7):3735-44. doi: 10.1128/JVI.02241-15.

17.

Optimized P2A for reporter gene insertion into Nipah virus results in efficient ribosomal skipping and wild-type lethality.

Park A, Yun T, Hill TE, Ikegami T, Juelich TL, Smith JK, Zhang L, Freiberg AN, Lee B.

J Gen Virol. 2016 Apr;97(4):839-43. doi: 10.1099/jgv.0.000405. Epub 2016 Jan 18.

18.

Temperature-sensitive mutations for live-attenuated Rift Valley fever vaccines: implications from other RNA viruses.

Nishiyama S, Ikegami T.

Front Microbiol. 2015 Aug 11;6:787. doi: 10.3389/fmicb.2015.00787. eCollection 2015. Review.

19.

MP-12 virus containing the clone 13 deletion in the NSs gene prevents lethal disease when administered after Rift Valley fever virus infection in hamsters.

Gowen BB, Westover JB, Sefing EJ, Bailey KW, Nishiyama S, Wandersee L, Scharton D, Jung KH, Ikegami T.

Front Microbiol. 2015 Jun 29;6:651. doi: 10.3389/fmicb.2015.00651. eCollection 2015.

20.

Rift Valley Fever Virus MP-12 Vaccine Is Fully Attenuated by a Combination of Partial Attenuations in the S, M, and L Segments.

Ikegami T, Hill TE, Smith JK, Zhang L, Juelich TL, Gong B, Slack OA, Ly HJ, Lokugamage N, Freiberg AN.

J Virol. 2015 Jul;89(14):7262-76. doi: 10.1128/JVI.00135-15. Epub 2015 May 6.

Supplemental Content

Loading ...
Support Center